相关实验视频
Updated: May 3, 2026

10:41
Culture and Co-Culture of Mouse Ovaries and Ovarian Follicles
Published on: March 17, 2015
22.7K
酸在老鼠模型中保护子宫和输卵管免受环胺诱导的毒性
1Department of Obstetrics and Gynecology, Faculty of Medicine, Nigde Omer Halisdemir University, Nigde 51240, Turkey.
Pharmaceuticals (Basel, Switzerland)
|January 8, 2025
概括
酸 (BA) 能防止循环胺 (CP) 治疗引起的生殖器官损伤. BA补充剂减少了暴露于CP的老鼠子宫和输卵管中的氧化应激和炎症.
科学领域:
- 生殖毒理学 生殖毒理学
- 药理学 药理学是指药理学的学科.
- 氧化应激研究研究 氧化应激研究
背景情况:
- 环胺 (CP) 是一种化疗剂,可以通过氧化应激和炎症引起生殖器官毒性.
- 保护生殖健康对癌症患者至关重要,特别是那些考虑未来怀孕的人.
- 酸 (BA) 具有抗氧化特性,可以减轻CP引起的损伤.
研究的目的:
- 调查玻尿酸 (BA) 在子宫和输卵管 (FT) 中对循环胺 (CP) 诱导的毒性产生保护作用.
- 在大鼠模型中评估BA在CP暴露后减少生殖组织中氧化应激和炎症的潜力.
主要方法:
- 40只雌性Wistar大鼠被分为控制,口服BA,CP和CP+口服BA组.
- 在14天内使用特定剂量方案诱导了CP毒性.
- 对子宫和FT组织进行了细胞病理学分析和对IL-6和HIF-1α的免疫组织化学评估.
主要成果:
- 脑膜炎治疗导致显著的子宫和FT损伤,包括上皮脱落,腺体退化和炎症.
- 在CP组中增加的HIF-1α和IL-6表达表明氧化应激和炎症增加.
- 在接受CP治疗的老鼠中,补充酸可以保持正常的组织结构,并减少氧化应激和炎症的标志物.
结论:
- 酸有效地减轻了小鼠的子宫和输卵管中循环胺诱导的损伤.
- BA在控制与CP相关的生殖毒性方面发挥了潜在的保护作用.
- 对BA作为接受CP治疗的患者的辅助疗法的进一步研究是有必要的.
相关概念视频
Oogenesis
58.4K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
58.4K
Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Ovarian Cycle
5.4K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.4K
Birth Control Methods
5.6K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.6K
Intrauterine Drug Delivery Systems
168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168

